Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07110636 · ClinicalTrials.gov registry record · NA

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

A NA study of Infection and Parasitic Disease, sponsored by Karius.

Recruiting
Registry status
NA
Development phase
2,000
Enrollment target
6
Study locations

NCT07110636: Recruiting NA study of Infection and Parasitic Disease, sponsored by Karius.

NCT07110636 is a NA study of Infection and Parasitic Disease that is actively recruiting participants, run by Karius. The registered enrollment target is 2,000 participants, above the 678-participant average among 41 other Infection trials with a reported enrollment target (195% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07110636, a NA study of Infection and Parasitic Disease, is actively recruiting participants, sponsored by Karius.

RECRUITING
Registry status
NA
Development phase
2,000 participants
Enrollment target
6
Study locations

Study Summary

This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection in the outpatient setting leads to faster infection diagnosis and treatment. Participants will give a blood sample one time to be used for the testing. Information about the participant's illness and any treatments within 30 days following enrollment will be recorded.

Primary Outcome

For each cohort, to evaluate whether the addition of Karius Spectrum testing to usual care testing reduces the time to identification of a pathogen-specific etiology, compared to usual care testing alone, in participants with suspected infection in the outpatient setting.

Interventions

  • DIAGNOSTIC_TEST Metagenomic plasma-based test for agnostic pathogen detection

Study Locations (6)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

California

  • University of California San Francisco - San Francisco

Louisiana

  • Ochsner Medical Center - New Orleans

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • Montefiore Medical Center - New York

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2025-10-27
Est. Completion 2028-12-31
Phase NA
Karius

7 total trials

What NCT07110636 shows while recruiting

NCT07110636 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 678-participant average among 41 other Infection trials with a reported enrollment target (195% higher).

The record links to 5 conditions, with Infection appearing as the primary indexed condition, and to 1 intervention - of which Metagenomic plasma-based test for agnostic pathogen detection is the first listed.

NCT07110636 lists 6 locations in 5 states (Massachusetts, California, Louisiana).

Frequently Asked Questions

What is clinical trial NCT07110636 about?

NCT07110636 is a clinical study titled "Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients". This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection in the outpatient setting leads to faster infection diagnosis and trea...

What is the current status of trial NCT07110636?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2025-10-27. Estimated completion is 2028-12-31.

What conditions does trial NCT07110636 study?

This clinical trial studies the following conditions: Infection, Parasitic Disease, Infections, Bacterial, Infections, Fungal, Infection Viral.

What interventions are being tested in trial NCT07110636?

The interventions under investigation include: Metagenomic plasma-based test for agnostic pathogen detection (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07110636?

This trial is sponsored by Karius, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07110636 being conducted?

This trial has 6 study locations across California, Louisiana, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07110636's enrollment target sits among peer trials

2,000 5th of 41 higher than 37 of 41 other Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07110636, the US trial registry maintained by the National Library of Medicine. NCT07110636 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.